- Home
- EXR vs RPRX Comparison
EXR vs RPRX Comparison
Compare EXR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXR | RPRX |
|---|---|---|
| Founded | 1977 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 25.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXR | RPRX |
|---|---|---|
| Price | $147.88 | $58.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $144.80 | $51.40 |
| AVG Volume (30 Days) | 920.8K | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | 1.90% |
| EPS Growth | ★ 13.90 | N/A |
| EPS | ★ 1.14 | 0.67 |
| Revenue | ★ $3,377,542,000.00 | $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $3.63 | $4.73 |
| P/E Ratio | $129.57 | ★ $87.81 |
| Revenue Growth | 3.70 | ★ 5.06 |
| 52 Week Low | $125.71 | $34.63 |
| 52 Week High | $155.19 | $59.72 |
Technical Indicators
Market Signals| Indicator | EXR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 59.54 |
| Support Level | $141.66 | $54.95 |
| Resistance Level | $148.54 | $58.84 |
| Average True Range (ATR) | 2.86 | 1.28 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 57.01 | 78.41 |
Price Performance
Historical ComparisonAbout EXR Extra Space Storage Inc
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.